Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ayman Grada

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
The Journal of Dermatological Treatment|December 11, 2024
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registryJonathan I Silverberg, Brian M Calimlim, Ayman Grada, et al.
Journal of the American Academy of Dermatology|May 7, 2023
Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohortJonathan I Silverberg, Brenda Simpson, Katrina Abuabara, et al.
Dermatology and Therapy|July 14, 2025
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)Jonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.
Italian Journal of Dermatology and Venereology|July 13, 2022
Masks trigger facial seborrheic dermatitis and psoriasis: evidence from a multicenter, case-control study during COVID-19 pandemicGiovanni Damiani, Renata Finelli, Khalaf Kridin, et al.
Frontiers in Medicine|January 3, 2022
The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 StudyGiovanni Damiani, Nicola Luigi Bragazzi, Chante Karimkhani Aksut, et al.
The Journal of Dermatological Treatment|May 11, 2026
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trialsEric L Simpson, Vimal H Prajapati, Christopher G Bunick, et al.
Nutrients|September 28, 2021
Diet-Related Phototoxic Reactions in Psoriatic Patients Undergoing Phototherapy: Results from a Multicenter Prospective StudyAlessia Pacifico, Rosalynn R Z Conic, Antonio Cristaudo, et al.
Journal of Drugs in Dermatology : JDD|April 7, 2023
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD RegistryEmma Guttman-Yassky, Jonathan Bar, Camille Rothenberg-Lausell, et al.
Italian Journal of Dermatology and Venereology|September 30, 2022
Facial atopic dermatitis may be exacerbated by masks: insights from a multicenter, teledermatology, prospective study during COVID-19 pandemicGiovanni Damiani, Renata Finelli, Khalaf Kridin, et al.
Dermatology and Therapy|June 26, 2025
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic DermatitisJonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
The Journal of Dermatological Treatment|December 11, 2024
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registryJonathan I Silverberg, Brian M Calimlim, Ayman Grada, et al.
Journal of the American Academy of Dermatology|May 7, 2023
Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohortJonathan I Silverberg, Brenda Simpson, Katrina Abuabara, et al.
Dermatology and Therapy|July 14, 2025
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)Jonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.
Italian Journal of Dermatology and Venereology|July 13, 2022
Masks trigger facial seborrheic dermatitis and psoriasis: evidence from a multicenter, case-control study during COVID-19 pandemicGiovanni Damiani, Renata Finelli, Khalaf Kridin, et al.
Frontiers in Medicine|January 3, 2022
The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 StudyGiovanni Damiani, Nicola Luigi Bragazzi, Chante Karimkhani Aksut, et al.
The Journal of Dermatological Treatment|May 11, 2026
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trialsEric L Simpson, Vimal H Prajapati, Christopher G Bunick, et al.
Nutrients|September 28, 2021
Diet-Related Phototoxic Reactions in Psoriatic Patients Undergoing Phototherapy: Results from a Multicenter Prospective StudyAlessia Pacifico, Rosalynn R Z Conic, Antonio Cristaudo, et al.
Journal of Drugs in Dermatology : JDD|April 7, 2023
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD RegistryEmma Guttman-Yassky, Jonathan Bar, Camille Rothenberg-Lausell, et al.
Italian Journal of Dermatology and Venereology|September 30, 2022
Facial atopic dermatitis may be exacerbated by masks: insights from a multicenter, teledermatology, prospective study during COVID-19 pandemicGiovanni Damiani, Renata Finelli, Khalaf Kridin, et al.
Dermatology and Therapy|June 26, 2025
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic DermatitisJonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, et al.
Pageof 10